Amgen's Trading Volume Drops 43% Ranking 177th Amid MariTide Phase 2 Study Anticipation

On June 18, 2025, Amgen's trading volume reached $416 million, marking a 43.22% decrease from the previous day and ranking 177th in the day's stock market activity. The company's stock price fell by 0.21%, extending its two-day losing streak with a total decline of 2.07%.

Amgen is set to present comprehensive results from the initial segment of its Phase 2 study on MariTide during the American Diabetes Association's 85th Scientific Sessions, scheduled for June 20-23, 2025, in Chicago. MariTide, a novel long-acting peptide-antibody formulation, is being evaluated for monthly or less frequent subcutaneous administration in individuals with obesity, with or without Type 2 diabetes. The findings will be shared in a dedicated symposium on June 23, from 1:30 p.m. to 3:00 p.m. CDT. This presentation will cover 52-week data related to the efficacy, safety, and tolerability observed in Part 1 of the Phase 2 trial, along with detailed outcomes from the primary analysis of the Phase 1 low dose pharmacokinetics study, and further insights into the Phase 3 MARITIME Chronic Weight Management research. Initial results from the Phase 2 study's Part 1 were previously disclosed in November 2024.

Amgen's MariTide is the first monthly or less frequently dosed peptide-antibody conjugate being investigated for the treatment of obesity and Type 2 diabetes. The company's shares have already risen 15% year-to-date on optimism around MariTide, and this data could push valuations higher if Phase 3 trials confirm its efficacy.

Amgen reported a 9% year-over-year revenue growth, with a 14% increase in volume, driven by strong demand for its innovative medicines. The company's biosimilars portfolio delivered over $700 million in revenue, marking a 35% increase year over year. Amgen launched three new products or indications and initiated four new Phase 3 studies, demonstrating robust pipeline progress. Repatha sales increased by 27% year over year, with significant improvements in patient access and a strong growth trajectory. The company received FDA approval for UPLIZNA in IgG4-related disease, expanding its rare disease portfolio and demonstrating its leadership in innovative treatments.

However, Amgen faced a 6% decline in net selling price, which partially offset the double-digit sales growth. Sales of TEPEZZA and KRYSTEXXA were adversely impacted by changes to US wholesaler inventory levels, affecting the rare disease portfolio's performance. The company anticipates fluctuations in quarterly sales for WEZLANA in the US, with no expected sales in the second quarter following a large first-quarter order. Amgen is navigating uncertainties related to tariffs and taxes, which could impact its long-term business strategy. The company expects non-GAAP R&D expenses to grow approximately 20% in 2025, reflecting increased investments in late-stage pipeline assets, which may pressure margins.